Drug Discovery, Pharmaceuticals & Cannabis Testing


Problem-free preparation of active form membrane proteins


AMSBIO announce a new range of Synthetic Nanodiscs that enable preparation of multi-pass transmembrane proteins in their active form, revolutionising the future of membrane protein research and drug development.


Membrane Proteins account for more than 60% of all FDA-approved drug targets and 90% of antibody-based drug targets. Many traditional sample preparation methods struggle with challenges in obtaining water-soluble and bioactive forms of multi-pass transmembrane proteins.


Commonly, detergent has been widely used to produce multi-pass transmembrane proteins. However, a major downside of this technique is that the detergent cannot be completely removed. This can be problematic for downstream applications, as the presence of detergent may interfere with experiments or affect the protein structure.


An alternative technique to obtain proteins with good solubility and correct folding is to use peptides derived from the N-terminus or extracellular loops. Unfortunately, transmembrane proteins prepared by this method may not retain the structural features and conformation of the original extracellular loops of the transmembrane protein in the native membrane.


Another method is to use membrane fractions, whole cells or VLPs to maintain the natural structure of transmembrane proteins, but immunisation with these products has been shown to result in high levels of non-specific antibody background.


Based upon an innovative polymer-based platform, Synthetic Nanodiscs offer a more advanced solution compared with these traditional solutions. Synthetic Nanodiscs have been shown, in multiple applications, to produce full-length membrane proteins with high purity and excellent solubility in aqueous solutions. Beneficially the proteins incorporated into Synthetic Nanodiscs are in a native membrane environment, ensuring they remain biologically active. There is no detergent in these products, making them suitable to use in cell- based assays and other experiments. Overall Synthetic Nanodiscs eliminate the need for membrane scaffold proteins, creating a streamlined cleaner system with reduced interference in downstream assays. In this way, our Synthetic Nanodiscs enable the functional characterisation of multi-pass transmembrane proteins in their active form, revolutionising the membrane protein research and drug development.


More information online: ilmt.co/PL/LxRo 63670pr@reply-direct.com


Advanced nucleic acid delivery solution for genetic medicine development


Thermo Fisher Scientific has launched Invitrogen™ Vivofectamine™ Delivery Solutions, a high-performance lipid nanoparticle (LNP) technology designed for the non-viral delivery of nucleic acids. This new LNP portfolio, derived from over 6,000 rationally designed ionisable lipids, offers in vivo delivery solutions with optimised efficiency, specificity, and safety profiles, accelerating progress in life science research and genetic medicine development.


One of the primary challenges in genetic medicine is safely and effectively delivering RNA or DNA to target cells without compromising integrity or causing adverse effects. The increasing adoption of LNP technology has been driven by the success of mRNA COVID-19 vaccines and growing concerns about the safety of viral delivery methods. LNP technology is gaining traction in gene replacement, cancer vaccines, gene editing therapies, and stem cell research, as well as in vivo and ex vivo immune cell therapies.


The Invitrogen Vivofectamine Delivery Solutions offer two specialised portfolios: the basic research portfolio for academic researchers and the drug development portfolio for biotechnology and biopharmaceutical companies. These portfolios help scientists reduce the time and cost of developing innovative genetic medicines.


“Building on decades of experience in lipid-based nucleic acid delivery, Vivofectamine LNPs are designed to facilitate safe and effective in vivo delivery of genetic material,” said Tiffani Manolis, Vice President of Cell Biology at Thermo Fisher Scientific. “These non-viral delivery solutions are


driving innovation in life sciences and paving the way for new breakthroughs in genetic medicine.”


Vivofectamine LNPs are available in a variety of formats, including reagent options and value-added services. They have been extensively tested in animal models, including studies for intramuscular delivery of vaccines and systemic liver delivery. Collaborators have also demonstrated feasibility for extra-hepatic delivery to immune cells, muscles, tumours, the central nervous system (CNS), and other tissues.


Designed for research use, Vivofectamine Delivery Solutions are ideal for academic institutions and drug developers seeking reliable in vivo delivery of nucleic acid therapies. More information online: ilmt.co/PL/65A4


63599pr@reply-direct.com


Preparation of cannabis samples for analysis


Neutral-to-analysis sample homogenization is the indispensable first step in the analysis process for cannabis and related products. Whether it is potency testing, extraction of CBD/THC or terpene or pesticide analysis – a truly homogeneous and representative sample always guarantees trustworthy analysis results. Retsch provides a wide range of lab mills suitable for the job.


As the Cannabis industry continues to grow, laws and regulations continue to evolve to ensure that the quality of the product meets the standards for safety and labeling. To obtain reliable and accurate results, the sample must be prepared properly. Retsch, as the world leader in sample preparation, provides laboratory mills for size reduction and sample homogenisation to ensure reliable analytical results.


Testing labs and manufacturers also continue in their testing demands and requirements to report compliance, regardless of product matrix, as the testing of Cannabis products includes both flower and edibles. Due to the complexity of the various matrices, there are many challenges to overcome in preparing the sample adequately for analysis.


Whether the samples are gummy bears, brownies, candies, or cannabis flower, Retsch can provide assistance in selecting the ideal instrument to meet the application requirements.


More information online: ilmt.co/PL/85vo 63501pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44